An Ancillary Pilot Trial Using Whole Genome Sequencing In Patients With Advance Refractory Cancer

Overview

When a patient with advanced cancer consults with a member of the Phase I drug development team, the investigators utilize all information possible to try to select a therapy for that patient which has the best chance of working for them. This information includes: 1. Past published information 2. Clinical experience and judgement 3. Immunohistochemistry for specific targets (e.g., ER) 4. Standard sequencing (e.g., for K-Ras) and other methods now available. The investigators have a new tool which warrants early exploration for what role it might eventually play in the process of selecting the best therapy for an individual patient. The basis of the current ancillary exploratory study is to gain initial experience with the operational aspects of this whole genome sequencing in this setting.

Full Title of Study: “An Ancillary Pilot Trial Using Whole Genome Sequencing In Patients With Advanced Refractory Cancer”

Study Type

  • Study Type: Observational
  • Study Primary Completion Date: March 2013

Detailed Description

1. To measure the time from biopsy to completion and final analysis of Whole Genome Sequencing (WGS) on patient tumor and non-tumor samples. 2. To examine the frequency with which useable sequence data is obtained as a function of tumor volume received and percent tumor involvement in the biopsy 3. To identify the frequency with which potential targets and pathways for therapy are discovered. 4. To observe for any evidence that if anti-tumor activity from treatment is noted how would the genome sequencing have correlated with that activity.

Clinical Trial Outcome Measures

Primary Measures

  • to identify as many genomic changes as possible in advanced cancers, so as to expand the range of potential actionable targets with therapies that were commercially available or clinical trials
    • Time Frame: 12 months

Participating in This Clinical Trial

Inclusion Criteria

  • Have a life expectancy of greater than 3 months. – Patients must have a diagnosis of histologically or cytologically confirmed advanced incurable cancer which has progressed on one or more prior chemotherapeutic, hormonal or biological regimens for advanced disease. – Be a good medical candidate for and willing to undergo a biopsy or surgical procedure to obtain tissue, which may or may not be part of the patient's routine care for their malignancy. Exclusion Criteria:

  • Patients with symptomatic CNS metastasis. – Known HIV, HBV or HCV infection requiring antiviral therapy. – Pregnant or breast-feeding patients or any patient with childbearing potential not using adequate contraception. – Inaccessible tumor for biopsy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Scottsdale Healthcare
  • Collaborator
    • National Foundation for Cancer Research
  • Provider of Information About this Clinical Study
    • Principal Investigator: Glen Weiss, Director, Clinical Research – Cancer Treatment Centers of America
  • Overall Official(s)
    • Glen J Weiss, M.D., Principal Investigator, Scottsdale Healthcare

Citations Reporting on Results

Weiss GJ, Liang WS, Demeure MJ, Kiefer JA, Hostetter G, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Phillips L, Benson H, Reiman R, Baker A, Marsh V, Von Hoff DD, Carpten JD, Craig DW. A pilot study using next-generation sequencing in advanced cancers: feasibility and challenges. PLoS One. 2013 Oct 30;8(10):e76438. doi: 10.1371/journal.pone.0076438. eCollection 2013.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.